>> Devin: ALL RIGHT, LARRY.
>> Kim: RESEARCHERS AROUND THE
WORLD ARE WORKING ON MORE THAN
165 DIFFERENT CORONAVIRUS
VACCINES, 31 OF THOSE ARE
CURRENTLY BEING TESTED IN
HUMANS.
WHILE WE’VE HEARD A LOT ABOUT A
HANDFUL OF THOSE VACCINES,
TONIGHT, OUR DR. FRANK McGEORGE
IS HERE WITH A LOOK AT TWO LESS
PUBLICIZED EFFORTS.
DOC?
>> Dr. McGeorge: SEVERAL EXPERTS
SAID THE FIRST CORONAVIRUS
VACCINES AVAILABLE MAY NOT
ULTIMATELY BE THE MOST
EFFECTIVE.
THERE ARE A WIDE VARIETY OF
APPROACHES BEING TRIED.
EVEN THE U.S. MILITARY IS
WORKING TOWARD ACCOMPLISHING THE
MISSION.
SCIENTISTS AT THE WALTER REED
HAVE PLAYED A MAJOR ROLE IN
VACCINE DEVELOPMENT BEFORE.
>> OUR INSTITUTION HAS BEEN AT
THE FOREFRONT OF ADDRESSING
EMERGING OUTBREAKS FOR OVER 100
YEARS.
>> Dr. McGeorge: IT HAS
CONTRIBUTED TO ABOUT HALF OF THE
VACCINES APPROVED IN THE U.S.
FOR VACCINES LIKE RUBELLA AND
INFLUENZA.
AND THEY USE A PROTEIN TO EXPOSE
THE IMMUNE SYSTEM TO THE
CORONAVIRUS’S SPIKE.
>> BY TAKING THE PROTEIN AWAY
FROM THE VIRUS AND PUTTING IT ON
TO STABLE PROTEIN, WE CAN
ACTUALLY GENERATE AN IMMUNE
RESPONSE WITHOUT ANY OF THE
ILLNESS ASSOCIATED.
>> Dr. McGeorge: THEIR GOAL IS
TO START HUMAN TRIALS BY THE END
OF SUMMER OR THIS FALL.
THE OTHER VACCINE IS THAT MADE
BY NOVA VAX.
AND WILL BEGIN IN 26 HEALTHY
ADULTS IN SOUTH AFRICA AND 240
ADULTS WITH HIV.
ADVOCACY GROUPS HAVE PUSHED FOR
PEOPLE WITH HIV TO BE INCLUDED
IN THE KRIN CAL TRIALS BECAUSE
THEIR IMMUNE SYSTEM MAY RESPOND
DIFFERENTLY AND PLANS TO LAUNCH
TRIALS IN THE U.S. IN THE NEAR
FUTURE.
THE WALTER REED VACCINE
CANDIDATE IS CONSIDERED A SECOND
TIER VACCINE AND PROBABLY READY
AFTER SOME OF THE FRONT RUNNERS
ALREADY PRODUCED MILLIONS OF
DOSES.
IF IT PROVES SUCCESSFUL, THE
COMPANY COULD DELIVER 100
MILLION DOSES FOR THE U.S. TO
USE IN THE FIRST MONTH OF 2021.
>> Kim: WHAT ARE THE ODDS THAT
WE GET A LOT OF VACCINES PROVING
EFFECTIVE AGAINST THE
CORONAVIRUS?
>> YOU KNOW, THAT IS CERTAINLY
POSSIBLE.
AND THAT’S THE HOPE, SINCE NO
SINGLE COMPANY COULD PRODUCE
ENOUGH DOSES TO MEET THE GLOBAL
DEMAND.
AND IT COULD BE THAT SOME WORK
BETTER IN DIFFERENT GROUPS LIKE
OLDER PEOPLE OR CHILDREN.
